Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study

Annals of Hematology

Volumn 91, Issue 4, 2012, Pages 543-551

  Kang, Hye Jin ^a   Kim, Won Seog ^b   Kim, Seok Jin ^b   Lee, Je Jung ^c   Yang, Deok Hwan ^c   Kim, Jin Seok ^d   Lee, Se Ryeon ^e   Lee, Gyeong Won ^f   Kim, Hyo Jung ^g   Kim, Ho Young ^g   Oh, Sung Yong ^h   Kim, Hugh Chul ⁱ   Eom, Hyeon Seok ^j   Chung, Jooseop ^k   Park, Jinny ^l   Suh, Cheolwon ^m   Ryoo, Baek Yeol ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Chonnam National University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Korea University College of Medicine   (South Korea)

^f Gyeongsang National University   (South Korea)

^g Hallym University   (South Korea)

^h Dong A University   (South Korea)

ⁱ Ajou University Medical Center   (South Korea)

^j National Cancer Center   (South Korea)

^k Pusan National University School of Medicine   (South Korea)

^l Gachon University College of Medicine   (South Korea)

^m University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

CVP; First line; Immunochemotherapy; Marginal zone lymphoma; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; MARGINAL ZONE LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SOUTH KOREA; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PREDNISOLONE; REPUBLIC OF KOREA; SURVIVAL RATE; VINCRISTINE;

EID: 84860805905     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1337-6     Document Type: Article

References (38)

1. Zinzani P, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, Molica S, Zaccaria A, Cantonetti AM, Gentilini P, Guardigni L, Gherlinzoni F, Ribersani M, Bendandi M, Albertini P, Tura S (1999) Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 17(4):1254-1258
2. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, Salles G, Coiffier B (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95(3):802-806
3. Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, López-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F, International Extranodal Lymphoma Study Group (2003) Nongastric marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue. Blood 101(7):2489-2495
4. Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, Kwon JM, Lee HR, Ko YH, Oh SJ, Park KW, Kim HJ, Kwon HC, Nam E, Kim JH, Park YH, Lee SS, Kim HY, Park K (2006) Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 85(11):781-786
5. Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K (2007) Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 82(6):446-452
6. Oh SY, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ (2007) Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. Cancer Lett 258(1):90-97
7. Oh SY, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ (2007) Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. Eur J Haematol 79 (4):287-291
8. Oh SY, Kim WS, Kim SJ, Kim JS, Kim SH, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Kim JG, Yang DH, Kang HJ, Choi CW, Park J, Choi YJ, Kim HJ, Kwon JH, Suh C, Kim HJ (2009) Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Am J Hematol 84 (12):826-829
9. Oh SY, Kim WS, Kim JS, Kim SJ, Kwon HC, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Lee GW, Choi CW, Park J, Suh C, Kim HJ (2010) Pulmonary marginal zone Bcell lymphoma of MALT type-what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy? Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol 89(6):563-568
10. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ (2010) Stage IV marginal zone B-cell lymphoma-prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Sci 101(11):2443-2447
11. Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR (1998) REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 83(4):806-812
12. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumours. Pathology & genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 1-351
13. Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Crump M (2001) Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 50(5):1258-1264
14. Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J, Takahashi H, Lennert K (1991) Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology 101(5):1159-1170
15. Zucca E, Bertoni F, Roggero E, Cavalli F (2000) The gastric marginal zone B-cell lymphoma of MALT type. Blood 96(2):410-419
16. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825-2833
17. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal- Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA (2000) European phase II study of rituximab (chimeric anti- CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18(2):317-324
18. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N (2002) Treatment of Waldenstroem's macroglobulinemia with rituximab. J Clin Oncol 20(9):2327-2333
19. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92 (6):1927-1932
20. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17(1):268-276
21. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19(2):389-397
22. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235-242
23. Conconi A, Martinelli G, Thieblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E (2003) Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102(8):2741-2745
24. Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E, Coiffier B (2000) Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 95(6):1950-1956
25. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417-1423
26. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26(28):4579-4586
27. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244-1253
28. Simon R (1987) How large should a phase II trial of a new drug be? Cancer Treat Rep 71(11):1079-1085
29. Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, Delchier JC (1995) Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 13(10):2524-2529
30. Zinzani PL, Stefoni V, Musuraca G, Tani M, Alinari L, Gabriele A, Marchi E, Pileri S, Baccarani M (2004) Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 100 (10):2190-2194
31. Rigacci L, Nassi L, Puccioni M, Mappa S, Polito E, Dal Pozzo S, Alterini R, Carrai V, Puccini B, Bosi A (2007) Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas. Ann Hematol 86(8):565-568
32. Orciuolo E, Buda G, Sordi E, Baraté C, Galimberti S, Ciancia E, Petrini M (2010) 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 34(2):184-189
33. Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C (2009) Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone Bcell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 115(22):5210-5217
34. Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R (2006) Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 24(10):1590-1596
35. Meloni G, Proia A, Guerrisi V, Cordone I, De Cuia R, Fenu S, Mauro FR, Pescarmona E, Reato G, Mandelli F (2000) Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation. Ann Oncol 11(11):1493-1495
36. Ma SY, Au WY, Chim CS, Lie AK, Lam CC, Tse E, Leung AY, Liang R, Kwong YL (2004) Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. Br J Haematol 124 (6):754-761
37. Foussard C, Colombat P, Maisonneuve H, Berthou C, Gressin R, Rousselet MC, Rachieru P, Pignon B, Mahé B, Ghandour C, Desablens B, Casassus P, Lamy T, Delwail V, Deconinck E (2005) Long-term follow-up of a randomized trial of fludarabine, mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. Ann Oncol 16(3):466-472
38. Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T (2006) Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non- Hodgkin's lymphoma. J Clin Oncol 24(1):174-180